A randomized phase II study of stem cell mobilization with cyclophosphamide plus G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma

Show full item record



Permalink

http://hdl.handle.net/10138/161109

Citation

Silvennoinen , R , Anttila , P , Saily , M , Lundan , T , Heiskanen , J , Siitonen , T M , Kakko , S , Putkonen , M , Ollikainen , H , Terava , V , Kutila , A , Launonen , K , Rasanen , A , Sikio , A , Suominen , M , Bazia , P , Kananen , K , Selander , T , Kuittinen , T , Remes , K & Jantunen , E 2016 , ' A randomized phase II study of stem cell mobilization with cyclophosphamide plus G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma ' , Bone Marrow Transplantation , vol. 51 , no. 3 , pp. 372-376 . https://doi.org/10.1038/bmt.2015.236

Title: A randomized phase II study of stem cell mobilization with cyclophosphamide plus G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma
Author: Silvennoinen, R.; Anttila, P.; Saily, M.; Lundan, T.; Heiskanen, J.; Siitonen, T. M.; Kakko, S.; Putkonen, M.; Ollikainen, H.; Terava, V.; Kutila, A.; Launonen, K.; Rasanen, A.; Sikio, A.; Suominen, M.; Bazia, P.; Kananen, K.; Selander, T.; Kuittinen, T.; Remes, K.; Jantunen, E.
Contributor: University of Helsinki, Clinicum
Date: 2016-03
Language: eng
Number of pages: 5
Belongs to series: Bone Marrow Transplantation
ISSN: 0268-3369
URI: http://hdl.handle.net/10138/161109
Abstract: The most common means of mobilizing autologous stem cells is G-CSF alone or combined with cyclophosphamide (CY) to obtain sufficient CD34(+) cells for one to two transplants. There are few prospective, randomized studies investigating mobilization regimens in multiple myeloma (MM), especially after lenalidomide-based induction. We designed this prospective, randomized study to compare low-dose CY 2 g/m(2)+G-CSF (arm A) and G-CSF alone (arm B) after lenalidomide-based up-front induction in MM. Of the 80 initially randomized patients, 69 patients were evaluable, 34 and 35 patients in arms A and B, respectively. The primary end point was the proportion of patients achieving a yield of >= 3x10(6)/kg CD34(+) cells with 1 - 2 aphereses, which was achieved in 94% and 77% in arms A and B, respectively (P = 0.084). The median number of aphereses needed to reach the yield of >= 3x10(6)/kg was lower in arm A than in arm B (1 vs 2, P = 0.035). Two patients needed plerixafor in arm A and five patients in arm B (P = 0.428). Although CY-based mobilization was more effective, G-CSF alone was successful in a great majority of patients to reach the defined collection target after three cycles of lenalidomide-based induction.
Subject: COLONY-STIMULATING FACTOR
DEXAMETHASONE COMBINATION
MARROW TRANSPLANTATION
THERAPY
BORTEZOMIB
BLOOD
COLLECTION
THALIDOMIDE
PLERIXAFOR
STRATEGIES
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
bmt2015236a_1_.pdf 406.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record